PUBLISHER: The Business Research Company | PRODUCT CODE: 1605559
PUBLISHER: The Business Research Company | PRODUCT CODE: 1605559
The treatment for desmoplastic small round cell tumor (DSRCT) involves various medical approaches, including surgery, chemotherapy, and radiation therapy, aimed at managing and controlling the progression of this rare and aggressive cancer. These treatments are designed to target and limit the spread of cancerous cells, particularly in the abdominal region. A significant benefit of DSRCT treatment is its potential to reduce tumor size, enhance survival rates, and improve the overall quality of life for patients.
The primary types of treatments in the desmoplastic small round cell tumor market include immunotherapy, surgical operations, chemotherapy, and radiotherapy. Immunotherapy is a treatment method that utilizes the body's immune system to combat diseases, especially cancer. The various drug classes involved comprise cytotoxic agents, targeted therapies, and immunomodulators, with multiple end users including hospitals, oncology clinics, and ambulatory surgical centers.
The desmoplastic small round cell tumor treatment market research report is one of a series of new reports from The Business Research Company that provides desmoplastic small round cell tumor treatment market statistics, including desmoplastic small round cell tumor treatment industry global market size, regional shares, competitors with a desmoplastic small round cell tumor treatment market share, detailed desmoplastic small round cell tumor treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the desmoplastic small round cell tumor treatment industry. This desmoplastic small round cell tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The desmoplastic small round cell tumor treatment market size has grown strongly in recent years. It will grow from $3.42 billion in 2023 to $3.7 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth observed during the historical period can be attributed to increased awareness of rare cancers, a rise in the number of clinical trials, enhanced funding for rare cancer research, greater availability of advanced diagnostics, and the expansion of immunotherapies and gene therapies.
The desmoplastic small round cell tumor treatment market size is expected to see strong growth in the next few years. It will grow to $5.11 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth during the forecast period can be attributed to the increasing number of specialized treatment centers, the rise of personalized medicine, a greater use of combination therapies, more new drug approvals, and an uptick in healthcare expenditures on cancer treatment. Key trends expected in this period include the adoption of targeted therapies, the integration of advanced diagnostics, the implementation of personalized medicine, advancements in gene editing technologies, and the development of improved drug delivery systems.
The growing emphasis on personalized medicine is projected to drive the growth of the desmoplastic small round cell tumor (DSRCT) treatment market in the future. Personalized medicine involves tailoring healthcare to an individual's unique genetic profile, lifestyle, and environment. It encompasses strategies such as pharmacogenomics, targeted therapies, and gene editing to deliver more precise and effective treatments. The increasing focus on personalized medicine is fueled by advancements in genomics, enhanced patient outcomes, and the potential for more targeted therapies. In the case of DSRCT, personalized medicine enables treatment strategies that are based on the specific genetic and molecular characteristics of the tumor, facilitating targeted therapies that enhance efficacy and minimize side effects. For example, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2022, the approval of 12 new personalized medicines accounted for approximately 34% of all new therapies approved, indicating a significant increase compared to previous years. Thus, the heightened focus on personalized medicine is a key driver of the DSRCT treatment market.
Increased investment in oncology research is also expected to support the growth of the desmoplastic small round cell tumor treatment market in the future. The rise in funding for oncology research is driven by the increasing incidence of cancer worldwide, advancements in precision medicine, and the need for innovative treatments to enhance patient outcomes. Research in oncology contributes to the treatment of DSRCT by improving the understanding of the tumor's biology, leading to the development of targeted therapies and better treatment protocols that improve patient outcomes. For instance, the National Cancer Institute, a US-based organization, reported in June 2024 that its budget for fiscal year 2022 was approximately $6.8 billion, reflecting a 5.7% increase from the previous year. Therefore, the growing investment in oncology research is propelling the DSRCT treatment market.
The increasing number of clinical trials is anticipated to drive the growth of the desmoplastic small round cell tumor treatment market moving forward. Clinical trials involve human volunteers and assess the safety and efficacy of new medical treatments or procedures, aiming to collect scientific data on their appropriateness for human use. The rise in clinical trials is largely attributed to advancements in medical research, the growing burden of diseases, regulatory changes, the globalization of clinical research, increased patient advocacy and awareness, competition within the industry, technological advancements, and new funding opportunities. Clinical trials provide access to innovative therapies and evaluate the effectiveness of new treatments, thereby improving patient outcomes and promoting the development of targeted and more effective treatment options. For instance, according to ClinicalTrials.gov, a US-based clinical trial registry, there were 477,225 clinical trials registered globally by the end of 2023, up from 437,506 trials registered in 2022. Thus, the rising number of clinical trials is contributing to the growth of the desmoplastic small round cell tumor treatment market.
Major companies operating in the desmoplastic small round cell tumor treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zymeworks Inc., Blueprint Medicines Corporation, MacroGenics Inc., Exelixis Inc
North America was the largest region in the desmoplastic small round cell tumor treatment market in 2023. The regions covered in the desmoplastic small round cell tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the desmoplastic small round cell tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The desmoplastic small round cell tumor treatment market includes revenues earned by entities by providing services such as immunotherapy, diagnostic imaging, and post treatment care, including rehabilitation and follow up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Desmoplastic Small Round Cell Tumor Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on desmoplastic small round cell tumor treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for desmoplastic small round cell tumor treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The desmoplastic small round cell tumor treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.